Immunotherapy Boosts Survival of Advanced Hodgkin Lymphoma
Medpage Today on MSN1d
Nivolumab Regimen Achieves Durable PFS in Advanced Hodgkin's LymphomaAdding nivolumab (Opdivo) instead of brentuximab vedotin (Adcetris) to the standard chemotherapy backbone of doxorubicin ...
Researchers investigated whether induction chemotherapy improves PFS and OS in patients with locally advanced cervical cancer ...
Discover key gene signatures that could help predict the efficacy of immune checkpoint blockade therapy in patients with ...
Patients with gallbladder cancer and cholangiocarcinoma may benefit from receiving Avastin plus Tarceva versus active ...
Sufferers who received the standard treatment, a drug called osimertinib, averaged 16.6 months of progression-free survival, the outlet revealed. The findings come as experts reportedly hail a ...
Long-term results support the use of capmatinib in patients with previously treated or untreated METex14 NSCLC, according to researchers.
For a subset of patients with inoperable or metastatic HR-positive/HER2-negative breast cancer, treatment with datopotamab ...
Patients with limited-stage SCLC were randomly assigned to receive durvalumab with or without tremelimumab or placebo as ...
Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent GlioblastomaCohort A Data ...
A new combination therapy of lurbinectedin and atezolizumab showed promising results in improving overall survival and ...
Jazz Pharmaceuticals’ Zepzelca, once on the brink of a market withdrawal, has returned with new trial results showing it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback